Glaucoma with hypertension: a comparison of treatment modality

Journal Title: International Journal of Medical Science and Public Health - Year 2015, Vol 4, Issue 12

Abstract

Background: As the intraocular pressure (IOP) increases, the risk of open-angle glaucoma (OAG) substantially increases. However, individuals with systemic hypertension at baseline exhibit one-half of the relative risk. The range of IOP fluctu - ation is larger in patients with untreated glaucoma; but, as some other studies deny it as independent risk factor, further studies are warranted. It is also established that drug effect varies with the timing of application. Thus, effect of amlodipine and atenolol should also vary. Objective: To compare the efficacy/safety of amlodipine versus atenolol in the glaucomatous hypertensive people using IOP control as the primary endpoint. Materials and Methods: IOP maxima, minima, and fluctuation were chosen as three separate outcome variables while minima, maxima, and fluctuations of systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean ocular perfusion pressure (MOPP) as predictor variables. The criteria and methods were decided as in the study by Choi et al. (Invest Ophthalmol Vis Sci 2006;47(3):831–6), with some modifications. We included freshly diagnosed patients of coex - istent “hypertension + glaucoma” and used amlodipine (5 mg OD)/atenolol (50 mg OD) + timolol (1 drop; 0.25% solution twice daily). Result: Baseline parameters showed no significant difference among the two groups. Amlodipine significantly changed all the three IOP and SBP parameters. SBP and DBP fluctuations increased but circadian MOPP fluctuation (CMF) decreased. Atenolol significantly changed all the three IOP parameters. Although peak SBP did not vary significantly, least SBP decreased and SBP fluctuation increased. DBP fluctuation and CMF decreased. Amlodipine and atenolol differed significantly in fluctuation effects—while amlodipine bettered on DBP fluctuation, atenolol bettered on IOP, SBP, and CMF fluctuations. Conclusion: Instead of SBP or DBP, their fluctuations show more effects. Atenolol is better than amlodipine in glaucomatous hypertensive people.

Authors and Affiliations

Navin Patel, Rakesh Ranjan Pathak

Keywords

Related Articles

Occurrence of neurocysticercosis in patients presenting with seizure and its radiological evaluation

Background: Neurocysticercosis (NCC) is a major parasitic disease affecting endemic areas worldwide. It spreads through fecal–oral route. It causes lesion in the central nervous system which has...

A study on analysis of blood donation deferral during blood donation camp at tertiary-care teaching hospital in south Gujarat region  

 Background: Blood is lifesaving medicine for critically ill patients. Blood donations save many lives in the world. With that blood is very important for vitality of humans. So, in the blood donations, it is very...

Association between allergic rhinitis and asthma symptoms in adults in Sudan  

 Background: Many published epidemiologic studies confirm a marked increase in the prevalence of asthma and allergic rhinitis (AR). Information is scarce regarding prevalence of AR and its association with asthma s...

Biosocial determinants of birth weight in a rural PHC of North Karnataka: a cross-sectional study

Background: Birth weight is influenced by various biosocial factors, and many unfavorable conditions may affect the health and general well-being of the mother. One particular factor cannot be attributed to the incid...

Investigation of the histological changes in spinal nerve roots post ıntrathecal ketamine administration

Background: Ketamine is a general anesthetic agent, administered intramuscularly or intravenously. It is generally used for induction and less frequently for the continuation of surgical anesthesia. Although ketamine was...

Download PDF file
  • EP ID EP133129
  • DOI 10.5455/ijmsph.2016.14092015103
  • Views 62
  • Downloads 0

How To Cite

Navin Patel, Rakesh Ranjan Pathak (2015). Glaucoma with hypertension: a comparison of treatment modality. International Journal of Medical Science and Public Health, 4(12), 1761-1766. https://europub.co.uk/articles/-A-133129